Cargando…

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

BACKGROUND: We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/dexamethasone) before autologous stem cell transplantation (ASCT). Here we compared the outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chim, Chor Sang, Lie, Albert Kwok Wai, Chan, Eric Yuk Tat, Liu, Herman Sung Yu, Lau, Ching Wa, Yip, Sze Fai, Sim, Joycelyn, Wan, Thomas Shek-Kong, Ma, Edmond Shiu-Kwan, Liang, Raymond, Tse, Eric, Kwong, Yok-Lam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418573/ https://www.ncbi.nlm.nih.gov/pubmed/22682027 http://dx.doi.org/10.1186/1756-8722-5-28

Ejemplares similares

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
por: Chim, Chor Sang
Publicado: (2010)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
por: Tse, Eric, et al.
Publicado: (2011)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
por: Wang, Lu Qian, et al.
Publicado: (2014)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series
por: MAO, JINGJUE, et al.
Publicado: (2014)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results
por: Gill, Harinder, et al.
Publicado: (2011)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin’s Lymphomas
por: Yim, Rita Lok-Hay, et al.
Publicado: (2012)

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013)

Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target
por: Tse, Eric, et al.
Publicado: (2015)

The diagnosis and management of NK/T-cell lymphomas
por: Tse, Eric, et al.
Publicado: (2017)

Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies
por: Tse, Eric, et al.
Publicado: (2022)

Lenalidomide-induced focal myocarditis mimicking acute ST segment elevation myocardial infarction
por: Tse, Yiu-Hei, et al.
Publicado: (2021)

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway
por: Wang, Lu Qian, et al.
Publicado: (2013)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
por: Hus, Iwona, et al.
Publicado: (2019)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2021)

Psychometric Characteristics of Different Versions of Vocal Tract Discomfort (VTD) Scale: A Systematic Review
por: Aghaei, Fateme, et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report
por: CHIM, CHOR SANG, et al.
Publicado: (2013)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

How we treat NK/T-cell lymphomas
por: Tse, Eric, et al.
Publicado: (2022)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
por: Chim, C. S., et al.
Publicado: (2010)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Improvement of myocardial perfusion reserve detected by cardiovascular magnetic resonance after direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery disease
por: Chan, Carmen Wing-Sze, et al.
Publicado: (2010)

T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression
por: Tse, Eric, et al.
Publicado: (2010)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Histiocytic sarcoma simulating immune thrombocytopenic purpura
por: Sim, Joycelyn, et al.
Publicado: (2012)

T-cell large granular lymphocyte leukemia: an Asian perspective
por: Kwong, Yok-Lam, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_c9e7p2up3jp03a0gcii87ndeih